Thera-SAbDab

CLERVONAFUSP

>   Structural Summary
TherapeuticClervonafusp
TargetSLC29A2
Heavy ChainEVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKALIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSRETFGAGTKLELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
Formatdi-Fab Fusion
IsotypeG1
Highest Clinical Trial (June '19)Phase-I/II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedValerion Therapeutics
Conditions Approvedna
Conditions ActiveGlycogen storage disease type II
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]